MedTrace Logo

Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

NCT04314011 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-17

No results posted yet for this study

Summary

The purpose of this clinical study is to answer the questions:

1. Is the proposed intervention safe?
2. Is the proposed intervention effective in improving the healthy status of subjects with aging frailty?

Conditions

  • Aging Frailty

Interventions

BIOLOGICAL

Human umbilical cord mesenchymal stem cells（HUC-MSCs）

Human umbilical cord mesenchymal stem cells（HUC-MSCs）

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Zhongming Liu, MD/Ph.D · Shanghai East Hospital, Shanghai Tongji University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-12-30
Completion
2022-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314011 on ClinicalTrials.gov